Deuterated pharmaceutical compositions and methods of treating cardiovascular diseases
Provided herein is a pharmaceutical composition comprising (i) a phosphodiesterase inhibitor or an adenosine receptor antagonist, (ii) a calcium channel blocker, (iii) a histamine H 1 -receptor agonist, a histamine H 2 -receptor agonist, or a histamine H 3 -receptor antagonist, and (iv) a β 2 -adrenoreceptor agonist; wherein at least one of two or more active pharmaceutical compounds is deuterium enriched. Also provided herein is a pharmaceutical composition comprising at least one of two or more deuterated compounds which increase pharmacokinetic half-life (increasing the duration of action) and reduce side effects by allowing for reduction of the dose levels. A method of use thereof pharmaceutical composition for treating, preventing, or ameliorating a cardiovascular disease.
1. The pharmaceutical composition, for treating or ameliorating bradycardia or cardiovascular disease with active pharmaceutical ingredients, comprising:
(i) theophylline or aminophylline 3.2-28.8 mg/dose, a subtherapeutically effective amount;
(ii) nifedipine 0.16-2.88 mg/dose, a subtherapeutically effective amount;
(iii) betahistine 0.4-10.8 mg/dose, a subtherapeutically effective amount;
(iv) levalbuterol or albuterol 0.03-1.08 mg/dose, a subtherapeutically effective amount;
wherein theophylline is deuterium-enriched no less than 50%.